“That being said, we've done a lot of work, and outside of the near-term temporary impact on bariatric surgery market we don't see these drugs impacting our growth outlook, even in the long-term.”

How to check this claim

Look at: Company's long-term revenue growth outlook/guidance (organic revenue growth rate), particularly for relevant surgical/device segments, as compared to previously stated targets

It came true if: Management-reaffirmed or achieved long-term organic growth guidance (e.g., mid-single-digit or higher, as originally framed) remains intact and not lowered due to GLP-1/anti-obesity drug impact, excluding a disclosed near-term bariatric surgery headwind

Where: Company earnings calls, investor day presentations, and 10-K/10-Q management discussion of growth drivers and guidance from 2024-2028

Verify independently

SEC filings for MDT ↗ · Claim quote is verbatim from the 2024Q2 earnings call.